We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

Synthetic Peptides to Pave Way for Diagnostic Tests to Detect Inflammatory Diseases

By LabMedica International staff writers
Posted on 24 May 2023
Print article
Image: Lateral flow assay detecting calprotectin in blood sample (Photo courtesy of BÜHLMANN & EPFL)
Image: Lateral flow assay detecting calprotectin in blood sample (Photo courtesy of BÜHLMANN & EPFL)

Common inflammatory disorders such as Crohn's disease and ulcerative colitis can be diagnosed or monitored by evaluating the protein calprotectin in fecal specimens, while serum levels of calprotectin can provide insight into inflammation status in rheumatoid arthritis. Calprotectin levels in patient samples are usually measured using antibodies that latch onto and identify the protein, such as in lateral flow assays. However, antibody-based calprotectin assays present a challenge: the outcomes can vary based on the type of antibody and test employed. This inconsistency arises because antibodies might attach to different sites on the protein or lack a uniform composition. Additionally, antibodies can become inactivated over time due to unfolding or precipitation.

A viable alternative could be employing peptides instead of antibodies to identify and quantify disease indicators like calprotectin. Peptides are sequences of up to 50 amino acids capable of binding to proteins with high specificity and affinity. Unlike antibodies, they can be synthetically produced with high purity and uniformity. Additionally, peptides are stable over time, cost less to produce, have lower inter-batch variability, and can be fixed to a specific location on a surface, simplifying the development of diagnostic assays by enabling a more precise and controlled method for biomarker detection. The use of synthetic peptides for detecting disease markers is highly promising as they are more accurate, reliable, and cost-effective than the commonly used antibodies in diagnostic tests.

BÜHLMANN Laboratories AG (Schönenbuch, Switzerland), in collaboration with a group of scientists at EPFL (Lausanne, Switzerland), has created a peptide that binds to the protein calprotectin, a key marker for major inflammatory disorders, demonstrating its suitability for diagnostic tests. From a library of over 500 billion different peptides, the researchers isolated several calprotectin binders and demonstrated their effectiveness for calprotectin quantification in simplified lateral flow assays. The top-performing peptide showed a dissociation constant of 26 nM, indicating its strong bond with calprotectin, making it a potential candidate for diagnostic tests.

The peptide developed binds not only to a large surface area of calprotectin but also to a specific form of calprotectin that is the relevant species in patient samples. The peptide was also tested in professionally assembled lateral flow cassettes and was found to be suitable for the accurate detection and quantification of calprotectin. In a proof-of-concept study, researchers used this setup to quantify calprotectin concentration in blood serum derived from patient samples. The peptide developed marks the first synthetic affinity agent that could be produced against the biomarker calprotectin.

“The EPFL and BÜHLMANN teams are currently performing more tests with the calprotectin-specific peptide to translate the assay into a product that can bring the diagnostic power of this increasingly important biomarker to a new level to help patients suffering from inflammatory diseases,” said Professor Christian Heinis at EPFL

“This collaboration greatly benefited from BÜHLMANN's knowhow to produce and handle the biomarker, and expertise of the EPFL team to generate and screen large combinatorial libraries of peptides by phage display,” added Christian Gerhold, CTO of BÜHLMANN.

Related Links:
BÜHLMANN Laboratories AG

Platinum Supplier
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Gold Supplier
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Supplier
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE

Print article


Clinical Chemistry

view channel
Image: A module with eight micro-devices, complete with microfluidic channels and drive motors (Photo courtesy of U.S Department of Energy)

Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses

Understanding the acidity or alkalinity of substances through pH measurement is crucial in many fields, from environmental monitoring to healthcare product safety. In many cases, these measurements must... Read more


view channel
Image: The QScout hematology analyzer has received US FDA 510(k) clearance (Photo courtesy of Ad Astra Diagnostics)

First Rapid-Result Hematology Analyzer Reports Measures of Infection and Severity at POC

Sepsis, a critical medical condition that arises as an extreme response to infection, poses a significant health threat. It occurs when an infection triggers a widespread inflammatory response in the body.... Read more


view channel
Image: PointCheck is the world’s first device for non-invasive white cell monitoring (Photo courtesy of Leuko Labs)

World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw

One of the toughest challenges for cancer patients undergoing chemotherapy is experiencing a low count of white blood cells, also known as neutropenia. These cells play a crucial role in warding off infections.... Read more


view channel
Image: Current testing methods for antibiotic susceptibility rely on growing bacterial colonies in the presence of antibiotics (Photo courtesy of 123RF)

Rapid Antimicrobial Susceptibility Test Returns Results within 30 Minutes

In 2019, antimicrobial resistance (AMR) was responsible for the deaths of approximately 1.3 million individuals. The conventional approach for testing antimicrobial susceptibility involves cultivating... Read more


view channel
Image: AI methods used in satellite imaging can help researchers analyze tumor images (Photo courtesy of Karolinska Institutet)

AI Approach Combines Satellite Imaging and Ecology Techniques for Analysis of Tumor Tissue

Advancements in tumor imaging technology have significantly enhanced our ability to observe the minute details of tumors, but this also brings the challenge of interpreting vast amounts of data generated... Read more


view channel
Image: Made-to-order diagnostic tests may soon be on the horizon (Photo courtesy of McGill University)

Breakthrough in Diagnostic Technology Could Make On-The-Spot Testing Widely Accessible

Home testing gained significant importance during the COVID-19 pandemic, yet the availability of rapid tests is limited, and most of them can only drive one liquid across the strip, leading to continued... Read more


view channel
Image: The acquisition significantly expands Medix Biochemica’s portfolio of IVD raw materials (Photo courtesy of ViroStat)

Medix Biochemica Acquires US-Based ViroStat to Expand Infectious Diseases Antibody Offering

Medix Biochemica (Espoo, Finland), a supplier of critical raw materials to the in vitro diagnostics (IVD) industry, has acquired ViroStat LLC (Portland, ME, USA), a provider of infectious disease antibodies... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.